HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD Offers Complex And Fast Tracks: Not All Advertising Claim Reviews Are Alike

Industry Self-Regulation Group Responds To Advertisers’ Suggestions

Executive Summary

NAD will assign three attorneys at the beginning of each Complex Track review instead of one, director Laura Brett said in a recent interview. The industry self-regulation group also recently launched its Fast-Track program for more simple ad claim challenges that rarely have been made.

You may also be interested in...



CRN Ends Funding For Industry Self-Regulation Program Focused On Supplement Advertising

The trade group ends funding for National Advertising Division program launched in 2006 for increased focus on monitoring supplement claims, reviewing 360 in total. Separately, NAD launches an expedited challenge process aiming to conclude reviews in 20 business days.

Disclosure Of Six-Hour Limit Clears Bayer To Claim Aleve ‘Better On Pain’ Than J&J's Tylenol

An appeals panel in the BBB National Programs, Inc. industry self-regulation program said Bayer should use a "six hour" qualifier with claims that its Aleve naproxen OTC is "better on pain" than J&J's Tylenol acetaminophen products.

Bayer's Aleve 'Proven Better' Than Tylenol Claims Fail In J&J Challenge At NAD

Bayer appeals to National Advertising Review Board over NAD’s finding the firm didn't support claims its Aleve OTC provides superior pain-relief to J&J’s Tylenol. It says NAD misunderstands scientific data and it will argue pain studies it submitted were methodologically sound and pain-relief statements were not overly broad.

Topics

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel